GlassScriptPhysician profile
Ashley Adams
NPI 1538465570
$3,680.28
in general payments reported to CMS, 2019-2025
37 companies · $268 in 2025
The $268 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,023 · 2022: $1,280 · 2023: $86.32 · 2024: $23.49 · 2025: $268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $378.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $377.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $468.28 | 2021-2023 | Vraylar |
| Novo Nordisk INC | $433.13 | 2021-2022 | |
| Lilly USA, LLC | $304.60 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $202.34 | 2021-2022 | |
| Glaxosmithkline, LLC. | $200.36 | 2021-2024 | Nucala |
| Janssen Pharmaceuticals, INC | $190.21 | 2021-2022 | |
| Pfizer INC. | $172.89 | 2021-2022 | |
| Amgen INC. | $167.66 | 2021-2025 | Tezspire |
| Astrazeneca Pharmaceuticals LP | $145.88 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $129.17 | 2021-2022 | |
| Eisai INC. | $116.83 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $116.05 | 2021 | |
| Supernus Pharmaceuticals, INC. | $110.29 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $89.24 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $79.81 | 2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $73.02 | 2025 | Dupixent |
| Nestle Healthcare Nutrition INC. | $69.71 | 2021-2022 | |
| Genzyme Corporation | $65.53 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $63.48 | 2021 | |
| Hikma Pharmaceuticals USA | $61.88 | 2023-2025 | Ryaltris |
| Scilex Pharmaceuticals INC. | $59.98 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $52.90 | 2021 | |
| Sanofi-Aventis U.S. LLC | $52.04 | 2021 | |
| Astellas Pharma US INC | $27.72 | 2025 | Veozah |
| Mylan Specialty L.P. | $25.38 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $22.63 | 2025 | Neffy |
| Alk-Abello, INC | $21.02 | 2023 | Grastek, Odactra, Ragwitek |
| Intra-Sana Laboratories | $20.83 | 2021 | |
| Merck Sharp & Dohme LLC | $20.57 | 2021 | |
| Esperion Therapeutics, INC. | $19.33 | 2022 | |
| Ibsa Pharma INC. | $17.06 | 2022 | |
| Sunovion Pharmaceuticals INC. | $15.05 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $14.84 | 2021 | |
| Genentech USA, INC. | $14.29 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.85 | 2021 | |
| Adlon Therapeutics L.P. | $11.79 | 2021 | |
| Phathom Pharmaceuticals, INC. | $10.64 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.